Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ANIXA BIOSCIENCES INC (ANIX : NSDQ)
 
 • Company Description   
Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.27 Daily Weekly Monthly
20 Day Moving Average: 97,324 shares
Shares Outstanding: 30.13 (millions)
Market Capitalization: $98.53 (millions)
Beta: 1.39
52 Week High: $5.87
52 Week Low: $2.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 28.24% 44.42%
12 Week 22.93% 35.14%
Year To Date 10.10% 37.82%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3150 ALMADEN EXPRESSWAY SUITE 250
-
SAN JOSE,CA 95118
USA
ph: 408-708-9808
fax: 631-549-5974
mcatelani@ituscorp.com http://www.anixa.com
 
 • General Corporate Information   
Officers
Amit Kumar - Chairman; President and Chief Executive Officer
Michael J. Catelani - Chief Operating Officer and Chief Financial Office
Lewis H. Titterton - Director
Arnold Baskies - Director
Emily Gottschalk - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03528H109
SIC: 2834
Fiscal Year
Fiscal Year End: October
Last Reported Quarter: 01/01/22
Next Expected EPS Date: 06/09/22
Share - Related Items
Shares Outstanding: 30.13
Most Recent Split Date: 6.00 (0.04:1)
Beta: 1.39
Market Capitalization: $98.53 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.52 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.96
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -44.44%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
04/30/22 - -
01/31/22 - -41.54
10/31/21 - -43.10
ROA
04/30/22 - -
01/31/22 - -39.80
10/31/21 - -41.17
Current Ratio
04/30/22 - -
01/31/22 - 19.58
10/31/21 - 28.33
Quick Ratio
04/30/22 - -
01/31/22 - 19.58
10/31/21 - 28.33
Operating Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Net Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Pre-Tax Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -2,559.06
Book Value
04/30/22 - -
01/31/22 - 1.10
10/31/21 - 1.16
Inventory Turnover
04/30/22 - -
01/31/22 - -
10/31/21 - -
Debt-to-Equity
04/30/22 - -
01/31/22 - 0.00
10/31/21 - 0.00
Debt-to-Capital
04/30/22 - -
01/31/22 - 0.00
10/31/21 - 0.00
 

Powered by Zacks Investment Research ©